MRSA vs. Dalvance: Let’s Get Ready To Rumble

Emily BurkeThe WEEKLY

MRSA’S MATCH Last week, the FDA approved Dalvance, Chicago-based Durata Therapeutic’s new antibacterial drug for the treatment of methicillin-resistant staphylococcus aureus (MRSA) infections. Why is Dalvance newsworthy? MRSA is an infectionthatis difficult to treat because it is resistant to all the usual medications: the cephalosporins and penicillins (methicillin, dicloxacillin, oxacillin, etc.) What is MRSA? MRSA skin infections may begin as … Read More

Don’t Be DOA. Learn The MOA.

Emily BurkeThe WEEKLY

MAJOR MECHANISMS OF ACTION The top selling drugs of 2013 were Abilify (Otsuka Pharmaceuticals; $6.9 billion), Nexium (AstraZeneca; $6.3 billion), and Humira (AbbVie; $5.9 billion). Anyone who follows biopharmaceuticals—and plenty of people who do not—are familiar with these drugs. How do they actually work? In this issue, we will take a look at the diverse mechanisms of action (MOA) of … Read More

Mitochondrial Medicine Going Mainstream?

Emily BurkeThe WEEKLY

MORE THAN “JUST” A POWERHOUSE When we hear the word mitochondria, most of us remember it described in high school biology class as the “powerhouse” of a cell. It is an apt moniker, and not just because mitochondria are the subcellular compartments that convert glucose from our diet into chemical energy that our cells can use to do work. These … Read More

Genome Editing: Curing HIV?

Emily BurkeGenetics, Genomics, The WEEKLY

CURING HIV? HIV destroys its victim’s immune system by infecting T-cells, a type of white blood cell critical for immunity. HIV binds to two different proteins on the T-cell’s surface: CD4 and CCR5. In the late 1990s, scientists identified a population of individuals seemingly resistant to HIV infection. Despite multiple known exposures, they did not get infected. It turned out … Read More